RxDoctor Payments Data

Sarit Patel, MD

Ophthalmic Plastic and Reconstructive Surgery · New Britain, CTNPI 1073500047

Payments from drug & device makers

$287in general payments, 2019–2025

Across 15 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$124
  • AbbVie$60
  • Alcon$31
  • Sun Pharmaceutical Industries Inc.$22
  • Bausch & Lomb Americas Inc.$21
  • Shire North American Group Inc$16
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$153,184
Medicare patients
319
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine46$65,271
XiidraLifitegrast26$47,876
LumiganBimatoprost37$28,675
Cyclosporine24$14,317
ErythromycinErythromycin Base347$3,077
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha207$2,231
Difluprednate16$1,449
Prednisolone Acetate28$1,205
Latanoprost30$594
MoxifloxacinMoxifloxacin Hcl11$287
Azithromycin37$141
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$140
Triamcinolone Acetonide26$93
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$60$93,94683 claims
Bausch & Lomb Americas Inc.Xiidra$21$47,87626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmic plastic and reconstructive surgery providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other ophthalmic plastic and reconstructive surgery in New Britain

Where these figures come from

Is this you, or does something look wrong? →